Patents Assigned to Pfizer
  • Patent number: 7595329
    Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: September 29, 2009
    Assignee: Pfizer Inc
    Inventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
  • Patent number: 7595325
    Abstract: The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or hydrate thereof, wherein L, R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating abnormal cell growth, such as cancer in a mammal by administering the compounds of formula 1.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: September 29, 2009
    Assignee: Pfizer Inc.
    Inventors: Matthew A. Marx, Jinshan Chen, Susan LaGreca
  • Patent number: 7592362
    Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: September 22, 2009
    Assignee: Pfizer Limited
    Inventors: Nathan Anthony Logan Chubb, Mark Roger Cox, Jerome Sebastien Dauvergne, Richard Andrew Ewin, Christelle Lauret
  • Publication number: 20090232848
    Abstract: This invention relates to methods for cultivating Lawsonia intracellularis. In particular, the present invention provides improved methods for cultivating Lawsonia intracellularis by employing reducing agents other than molecular hydrogen; or alternatively, by employing a combination of one or more reducing agents with molecular hydrogen. This invention also relates to vaccines and diagnostic reagents prepared from Lawsonia intracellularis cultivated by employing the methods disclosed herein.
    Type: Application
    Filed: November 14, 2005
    Publication date: September 17, 2009
    Applicant: PFIZER INC.
    Inventor: Srinivas Saginala
  • Publication number: 20090233813
    Abstract: Bicyclo-pyrazole compound of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, processes for their preparation, combinatorial libraries comprising a plurality of them and pharmaceutical compositions thereof, are herewith disclosed: the compounds of the invention are useful, in therapy, as protein kinase inhibitors, for instance in the treatment of cancer.
    Type: Application
    Filed: May 27, 2009
    Publication date: September 17, 2009
    Applicant: PFIZER ITALIA S.R.L.
    Inventors: Roberto Tonani, Simona Bindi, Daniele Fancelli, Valeria Pittala', Mario Varasi
  • Patent number: 7589109
    Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: September 15, 2009
    Assignee: Pfizer Inc
    Inventors: Chikara Uchida, Hiroki Sone, Kiyoshi Kawamura
  • Publication number: 20090227680
    Abstract: The present invention relates to a method of treating pain using a compound of formula (I), wherein Ar, R1, R3 and R3a are as defined herein. The invention also relates to certain novel compounds of formula (I).
    Type: Application
    Filed: November 6, 2006
    Publication date: September 10, 2009
    Applicant: Pfizer, Inc.
    Inventor: Simon John Mantell
  • Publication number: 20090227562
    Abstract: The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phospho-diesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain.
    Type: Application
    Filed: July 8, 2005
    Publication date: September 10, 2009
    Applicant: Pfizer Inc.
    Inventor: Bernadette Hughes
  • Patent number: 7585869
    Abstract: The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R11, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: September 8, 2009
    Assignee: Pfizer, Inc.
    Inventors: Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
  • Publication number: 20090221632
    Abstract: Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.
    Type: Application
    Filed: May 13, 2009
    Publication date: September 3, 2009
    Applicant: PFIZER ITALIA S.R.L.
    Inventors: Daniele Fancelli, Valeria Pittala, Mario Varasi
  • Patent number: 7582643
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: September 1, 2009
    Assignee: Pfizer Inc
    Inventors: Tanisha D. Blake, Bruce C. Hamper, Wei Huang, James R. Kiefer, Jr., Joseph B. Moon, Bradley E. Neal, Kirk L. Olson, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, John I. Trujillo, Steven R. Turner
  • Patent number: 7582611
    Abstract: Compounds having a structure according to formula (I) where RA, RB, RC, RD, RE, and RF are as defined herein, are useful as prokinetic agents.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: September 1, 2009
    Assignee: Pfizer Inc.
    Inventors: Yaoquan Liu, Christopher Carreras, David C. Myles, Yong Li, Simon James Shaw, Hong Fu, Yue Chen, Hao Zheng, Yandong Li, Mark A. Burlingame
  • Patent number: 7582628
    Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: September 1, 2009
    Assignee: Pfizer Italia S.r.l.
    Inventors: Daniele Fancelli, Barbara Forte, Jürgen Moll, Mario Varasi, Paola Vianello
  • Publication number: 20090215857
    Abstract: The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 29, 2006
    Publication date: August 27, 2009
    Applicant: Pfizer Products Inc.
    Inventors: Thomas Bruno Lanni, Scott Edward Lazerwith, Susan Mary Kult Sheehan, Anthony Jerome Thomas
  • Publication number: 20090215891
    Abstract: A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, and methods of treating conditions characterized by an overexpression on nitric oxide from the inducible isoform of nitric oxide synthase using the S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride.
    Type: Application
    Filed: December 5, 2008
    Publication date: August 27, 2009
    Applicant: Pfizer, Inc.
    Inventors: Lyle Brostrom, Ann Czyzewski, Vahid Zia, Ahmad Sheikh
  • Patent number: 7579340
    Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: August 25, 2009
    Assignee: Pfizer Inc
    Inventors: Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
  • Patent number: 7579471
    Abstract: The present invention provides compounds of formula (I) wherein X, Y, R1, R2 and R3 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: August 25, 2009
    Assignee: Pfizer, Inc.
    Inventors: Patricia Ann Basford, Peter Thomas Stephenson, Stefan Colin John Taylor, Anthony Wood
  • Publication number: 20090209577
    Abstract: This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula: wherein R1, R2 and R3, are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
    Type: Application
    Filed: August 8, 2005
    Publication date: August 20, 2009
    Applicant: PFIZER INC.
    Inventors: Paul V. Rucker, Kevin D. Jerome, Shaun R. Selness, John E. Baldus, Li Xing
  • Patent number: 7576081
    Abstract: The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: August 18, 2009
    Assignee: Pfizer Inc.
    Inventors: Charlotte Moira Norfor Allerton, Andrew Douglas Baxter, Andrew Simon Cook, David Hepworth, Stephen Kwok-Fung Wong
  • Patent number: 7576128
    Abstract: The present invention is directed to a new class of 4-oxo-benzonitriles, their use as androgen modulators, and to their use in the treatment of alopecia.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: August 18, 2009
    Assignee: Pfizer Inc.
    Inventors: Lain-Yen Hu, Huangshu Lei, Daniel Y. Du, Bruce A. Lefker